Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jan 29;29(1):39.
doi: 10.1007/s11916-024-01322-7.

Pain and Headache in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease

Paulina Diaz  1 , Nancy E Nealon  1 , Ulrike W Kaunzner  2
Affiliations
Review

Pain and Headache in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease

Paulina Diaz et al. Curr Pain Headache Rep. .

Abstract

Purpose of review: The purpose of this review is to evaluate the current knowledge and recent findings on different pain and headache presentations associated with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) disease.

Recent findings: MOGAD is an inflammatory autoimmune disease affecting mostly the central nervous system, presenting with optic neuritis, transverse myelitis and other forms of inflammatory demyelination. Pain and headache in MOGAD have been recognized more recently and acute and chronic forms of pain can occur in both the adult and pediatric population. An important recent observation is that MOGAD can affect the peripheral nervous system, which can contribute to pain symptoms. Acute and chronic forms of pain have been described in MOGAD, including ocular pain, different types of headaches and neuropathies, involving the central and peripheral nervous system. Awareness of these types of pain in both the pediatric and adult population is crucial, to ensure timely diagnosis and treatment.

Keywords: Headache; MOGAD; Myelin oligodendrocyte glycoprotein; Neuropathy; Optic neuritis; Pain.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing Interests: The authors declare no competing interests. Human and Animal Rights and Informed Consen: This article does not contain any studies with human or animal subjects performed by any of the authors.

References

    1. Marignier R, Hacohen Y, Cobo-Calvo A, Probstel AK, Aktas O, Alexopoulos H, et al. Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol. 2021;20(9):762–72. https://doi.org/10.1016/S1474-4422(21)00218-0 . - DOI - PubMed
    1. Cortese R, Battaglini M, Prados F, Bianchi A, Haider L, Jacob A, et al. Clinical and MRI measures to identify non-acute MOG-antibody disease in adults. Brain. 2023;146(6):2489–501. https://doi.org/10.1093/brain/awac480 . - DOI - PubMed
    1. Longbrake E. Myelin oligodendrocyte glycoprotein-associated disorders. Continuum (Minneap Minn). 2022;28(4):1171–93. https://doi.org/10.1212/CON.0000000000001127 . - DOI - PubMed - PMC
    1. Cacciaguerra L, Redenbaugh V, Chen JJ, Morris P, Sechi E, Syc-Mazurek SB, et al. Timing and predictors of T2-lesion resolution in patients with myelin oligodendrocyte glycoprotein antibody-associated disease. Neurology. 2023;101(13):e1376–81. https://doi.org/10.1212/WNL.0000000000207478 . - DOI - PubMed - PMC
    1. Corbali O, Chitnis T. Pathophysiology of myelin oligodendrocyte glycoprotein antibody disease. Front Neurol. 2023;14:1137998. https://doi.org/10.3389/fneur.2023.1137998 . - DOI - PubMed - PMC

MeSH terms

Substances

LinkOut - more resources